Tim Tully, Ph.D. Executive Vice President of R&D & Chief Science Officer
Dr. Tully has studied the genetic basis of memory for his entire career. In 1994, he and his group at Cold Spring Harbor Laboratory discovered that a gene called CREB plays an important role in regulating the conversion of short-term memory to long-term memory. This finding suggested that small molecule modulators of the CREB pathway might enhance memory and, therefore, would be useful in treating memory-related disorders such as Alzheimer's disease. With the aide of Jim Watson, Dr. Tully found Helicon Therapeutics, Inc. in 1997, and was Acting Chief Science Officer until 2012 when Helicon merged with Dart NeuroScience LLC. Dr. Tully received B.S.s in Biology and in Psychology from the University of Illinois in 1976 and a Ph.D. in Genetics in 1981. He pursued postdoctoral training in NeuroGenetics at Princeton University and in Molecular Genetics at M.I.T. In 1987, Dr. Tully became an Assistant Professor at Brandeis University, and in 1991 joined the staff of Cold Spring Harbor Laboratory as an Associate Professor, became Professor in 1995, The St. Giles Professor of Neuroscience in 2003, Head of the Division of Neurogenetics in 2006 and finally resigned his professorship at CSHL in 2007 to become Chief Science Officer of Dart Neuroscience LLC. He also is an Adjunct Professor at Tsinghua University in Beijing China and at the National Tsing Hua University in Hsin Chu Taiwan. Dr. Tully has published numerous scientific papers and is on the editorial board of several neuroscience journals. He is the recipient of numerous awards and honors for his research.